Clinical Trial

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

Name: Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers — clinical trial record (NCT07259226)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: OASIS

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types.

Trial Details

NCT Number	NCT07259226
Lead Sponsor	UNICANCER
Conditions	Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer, Advanced Non Small Cell Lung Cancer (NSCLC)
Enrollment	400 participants
Start Date	2025-11-14
Primary Completion	2030-11-01 (estimated)
Study Completion	2030-11-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-02